{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Veracyte, Inc. overvalued or undervalued?
As of October 24, 2025, Veracyte, Inc. is considered undervalued with attractive metrics, including a P/E ratio of 56 and a PEG ratio of 0.12, despite a 12.05% stock return over the past year, which is lower than the S&P 500's 16.90%, but it has outperformed the index over three years with a return of 128.70%.
Veracyte, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Veracyte, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 56 and a price-to-book value of 1.80. The company exhibits a unique growth outlook with a PEG ratio of 0.12, while its stock performance reflects a 1-week return of 2.51% and a 128.70% return over three years.
Is Veracyte, Inc. overvalued or undervalued?
As of October 24, 2025, Veracyte, Inc. is considered undervalued with a favorable valuation grade shift, showing a P/E ratio of 56, a Price to Book Value of 1.80, and an EV to EBITDA of 35.87, while outperforming the S&P 500 in the short term despite challenges.
Is Veracyte, Inc. overvalued or undervalued?
As of October 24, 2025, Veracyte, Inc. is considered undervalued with an attractive valuation grade, reflected by a P/E ratio of 56 and strong growth potential, despite a year-to-date return of -7.25%, while outperforming the S&P 500 over three years with a return of 128.70%.
Veracyte, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape
Veracyte, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 56 and a low PEG ratio of 0.12, suggesting potential growth. Compared to peers, its performance metrics vary, with a year-to-date return of -9.52%, but a notable three-year return of 113.53%.
Veracyte, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Veracyte, Inc. has recently revised its evaluation amid changing market conditions. The stock, priced at $35.83, has shown a 4.43% return over the past year, lagging behind the S&P 500. Despite recent challenges, Veracyte has achieved a notable 113.53% return over the last three years.
Veracyte, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Veracyte, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $36.04, with a 9.74% return over the past year, lower than the S&P 500. However, it has achieved a 94.92% return over three years, outperforming the index during that period.
Is Veracyte, Inc. technically bullish or bearish?
As of October 3, 2025, Veracyte, Inc. shows a mildly bullish trend driven by strong weekly indicators, despite mixed signals in longer time frames and a recent outperformance against the S&P 500.
Is Veracyte, Inc. technically bullish or bearish?
As of October 3, 2025, Veracyte, Inc. shows a mildly bullish trend with positive weekly indicators, despite mixed signals from MACD and moving averages, and has outperformed the S&P 500 in the short term.
Is Veracyte, Inc. technically bullish or bearish?
As of October 3, 2025, Veracyte, Inc. shows a mildly bullish trend with strong weekly indicators, despite being down 9.09% year-to-date, while outperforming the S&P 500 in the short term.
Is Veracyte, Inc. technically bullish or bearish?
As of September 9, 2025, Veracyte, Inc. shows a neutral trend with mixed indicators, including mildly bullish weekly MACD and bearish monthly MACD, while outperforming the S&P 500 recently but underperforming year-to-date, suggesting a cautious investment approach.
Is Veracyte, Inc. overvalued or undervalued?
As of September 10, 2025, Veracyte, Inc. is considered overvalued with a P/E ratio of 56 and an EV to EBITDA of 35.87, despite recent short-term outperformance against the S&P 500, as it has underperformed year-to-date with a return of -16.09%.
Is Veracyte, Inc. overvalued or undervalued?
As of May 7, 2025, Veracyte, Inc. is fairly valued with a P/E ratio of 56 and a PEG ratio of 0.12, indicating competitive positioning and potential growth despite a year-to-date stock decline of 32.55%.
Is Veracyte, Inc. technically bullish or bearish?
As of June 11, 2025, Veracyte, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD and moving averages, while the RSI and OBV show no strong momentum.
Who are in the management team of Veracyte, Inc.?
As of March 2022, Veracyte, Inc.'s management team includes Ms. Bonnie Anderson as Chairman and CEO, along with Mr. John Bishop (Lead Independent Director), Mr. Jens Holstein, Dr. Frederick Cohen, Ms. Karin Eastham, and Dr. Robert Epstein as Directors.
What does Veracyte, Inc. do?
Veracyte, Inc. is a genomic diagnostics company in the Pharmaceuticals & Biotechnology sector, with a market cap of approximately $2.1 billion. As of March 2025, it reported net sales of $114 million and a net profit of $7 million.
How big is Veracyte, Inc.?
As of Jun 18, Veracyte, Inc. has a market capitalization of $2.1 billion, with net sales of $463.39 million and a net profit of $33.04 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
